SELLAS Life Sciences Group Inc (SLS)
1.46
-0.01
(-0.68%)
USD |
NASDAQ |
May 17, 16:00
1.465
0.00 (0.00%)
After-Hours: 20:00
SELLAS Life Sciences Group Enterprise Value: 65.91M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 65.91M |
| May 16, 2024 | 66.48M |
| May 15, 2024 | 66.48M |
| May 14, 2024 | 60.71M |
| May 13, 2024 | 60.71M |
| May 10, 2024 | 59.84M |
| May 09, 2024 | 56.09M |
| May 08, 2024 | 55.51M |
| May 07, 2024 | 57.82M |
| May 06, 2024 | 56.09M |
| May 03, 2024 | 58.40M |
| May 02, 2024 | 59.55M |
| May 01, 2024 | 55.51M |
| April 30, 2024 | 53.20M |
| April 29, 2024 | 51.47M |
| April 26, 2024 | 65.91M |
| April 25, 2024 | 69.37M |
| April 24, 2024 | 68.24M |
| April 23, 2024 | 73.30M |
| April 22, 2024 | 68.24M |
| April 19, 2024 | 68.24M |
| April 18, 2024 | 67.11M |
| April 17, 2024 | 60.92M |
| April 16, 2024 | 58.11M |
| April 15, 2024 | 56.42M |
| Date | Value |
|---|---|
| April 12, 2024 | 56.98M |
| April 11, 2024 | 60.36M |
| April 10, 2024 | 59.80M |
| April 09, 2024 | 60.36M |
| April 08, 2024 | 62.89M |
| April 05, 2024 | 56.98M |
| April 04, 2024 | 54.17M |
| April 03, 2024 | 55.30M |
| April 02, 2024 | 47.98M |
| April 01, 2024 | 41.79M |
| March 28, 2024 | 54.30M |
| March 27, 2024 | 55.43M |
| March 26, 2024 | 57.11M |
| March 25, 2024 | 55.99M |
| March 22, 2024 | 56.48M |
| March 21, 2024 | 53.17M |
| March 20, 2024 | 54.82M |
| March 19, 2024 | 55.37M |
| March 18, 2024 | 43.82M |
| March 15, 2024 | 46.03M |
| March 14, 2024 | 64.88M |
| March 13, 2024 | 62.27M |
| March 12, 2024 | 57.48M |
| March 11, 2024 | 56.40M |
| March 08, 2024 | 52.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.486M
Minimum
Jun 30 2019
183.79M
Maximum
Jun 28 2021
44.87M
Average
29.29M
Median
Enterprise Value Benchmarks
| Geron Corp | 1.900B |
| Immuneering Corp | -27.69M |
| Protagonist Therapeutics Inc | 1.480B |
| Akebia Therapeutics Inc | 229.22M |
| Moderna Inc | 42.41B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.566M |
| Total Expenses (Quarterly) | 9.645M |
| EPS Diluted (Quarterly) | -0.21 |
| Earnings Yield | -75.34% |
| Normalized Earnings Yield | -146.86 |